Plus Therapeutics, Inc.
PSTV
$0.59
$0.00-0.07%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.50% | 31.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.50% | 31.26% | |||
| Cost of Revenue | 95.51% | -29.04% | |||
| Gross Profit | -821.53% | 120.66% | |||
| SG&A Expenses | 104.70% | -40.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 100.79% | -36.28% | |||
| Operating Income | -191.42% | 56.50% | |||
| Income Before Tax | -185.87% | 129.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -185.87% | 129.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -185.87% | 129.60% | |||
| EBIT | -191.42% | 56.50% | |||
| EBITDA | -201.51% | 56.90% | |||
| EPS Basic | -267.48% | 100.08% | |||
| Normalized Basic EPS | -138.65% | 100.28% | |||
| EPS Diluted | -533.85% | 99.98% | |||
| Normalized Diluted EPS | -266.88% | 100.06% | |||
| Average Basic Shares Outstanding | 122.01% | 10,525.58% | |||
| Average Diluted Shares Outstanding | -48.64% | 45,827.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||